UY36948A - Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial - Google Patents

Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial

Info

Publication number
UY36948A
UY36948A UY0001036948A UY36948A UY36948A UY 36948 A UY36948 A UY 36948A UY 0001036948 A UY0001036948 A UY 0001036948A UY 36948 A UY36948 A UY 36948A UY 36948 A UY36948 A UY 36948A
Authority
UY
Uruguay
Prior art keywords
corticosteroid
formulations
analgesic effect
maintain
release
Prior art date
Application number
UY0001036948A
Other languages
English (en)
Inventor
Neil Bodick
Derek Jackson
Toni Williamson
Original Assignee
Flexion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flexion Therapeutics Inc filed Critical Flexion Therapeutics Inc
Publication of UY36948A publication Critical patent/UY36948A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención refiere a composiciones y métodos para obtener y mantener un máximo efecto analgésico luego de administración intra-articular de formulaciones de corticosteroides. También describe formulaciones de liberación extendida, por ejemplo, formulaciones de corticosteroides de liberación controlada o sostenida, incluyendo formulaciones de liberación extendida, por ejemplo, formulaciones de liberación controlada o sostenida de acetonida de triamcinolona (TCA), propionato de fluticasona, cortisol, ciclesonida (monopropionato), dipropionato de beclometasona, dexametasona, flunisolida, budesonida, desisobutiril-ciclesonida, y/o furoato de mometasona, que producen máximo efecto analgésico mayor al efecto analgésico agudo proporcionado por suspensiones de corticosteroides estándar, y que también se asocian con efecto clínicamente insignificante sobre producción de cortisol endógeno luego de administración.
UY0001036948A 2015-10-13 2016-10-13 Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial UY36948A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562240811P 2015-10-13 2015-10-13

Publications (1)

Publication Number Publication Date
UY36948A true UY36948A (es) 2017-05-31

Family

ID=58498560

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036948A UY36948A (es) 2015-10-13 2016-10-13 Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial

Country Status (5)

Country Link
US (1) US20170100411A1 (es)
AR (1) AR106330A1 (es)
TW (1) TW201726145A (es)
UY (1) UY36948A (es)
WO (1) WO2017066423A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI843284B (zh) * 2021-11-11 2024-05-21 中央研究院 診斷及治療骨關節炎的方法
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
WO2014153384A1 (en) * 2013-03-19 2014-09-25 Flexion Therapeutics, Inc. Corticosteroid formulations for the treatment of joint pain and methods of use thereof
BR112015024234B1 (pt) * 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas

Also Published As

Publication number Publication date
TW201726145A (zh) 2017-08-01
AR106330A1 (es) 2018-01-03
WO2017066423A1 (en) 2017-04-20
US20170100411A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
CO2017003396A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
BR112014027681B8 (pt) Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação
BR112015023629A8 (pt) Formulação de acetato de abiraterona
MX2018014978A (es) Composiciones nasales de cannabidiol.
ECSP17057848A (es) Composiciones farmacéuticas para terapia combinada
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2018001192A1 (es) Análogos de saponina triterpeno
BR112013012587A2 (pt) composição farmacêutica para administração nasal
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
MX2018006800A (es) Composicion farmaceutica.
CL2019001092A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
AR097078A1 (es) Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
UY34899A (es) Derivados de estra-1,3,5(10), 16-tetraeno 3-sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, asi como su uso para la preparación de medicamentos
EP3397248A4 (en) PHARMACEUTICAL COMPOSITION WITH DUTASTERIDE AND PROPYLENE GLYCOL MONOLARATE AND METHOD OF MANUFACTURING THEREOF
CO2019002245A2 (es) Combinación de agonistas de fxr
UY36948A (es) Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial
MX2021012029A (es) Composicion farmaceutica de corticosteroide soluble.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221129